Slide 1: Immuron CEO to present at TechKnow Invest Roadshow
Immuron CEO, Steven Lydeamore to present at TechKnow Invest Roadshow Melbourne, Australia, July 31, 2024: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be present
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine
Slide 3: References
References Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012. Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium diff
Slide 4: TechKnow Invest Roadshow
NASDAQ: IMRN ASX: IMC For personal use only TechKnow Invest Roadshow Steven Lydeamore Chief Executive Officer 31 JULY 2024
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Technology platform
Technology platform Immuron’s proprietary technology platform For personal use only combines the natural human nutrition & health benefits of bovine colostrum with a novel class of specifically targeted oral polyclonal antibodies that offer delivery within the gastrointestinal (“GI”) tract and can b
Slide 8: Travelan Mechanism of action
Travelan® | Mechanism of action Pre-Clinical Studies For personal use only Broad spectrum antimicrobial Protects against bacterial Binds to surface layer proteins Toxin neutralization and adhesion to host cell intestinal preventing bacterial clearance of targeted gut epithelia colonization and motil
Slide 9: Addressable market & industry overview
Addressable market & industry overview Billion Dollar Market For personal use only Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7% Industry tailwinds Travel picking up significantly following COVID lockdowns Frequent Symptom 30% - 70% of travelers experience traveller’s
Slide 10: Travelan record sales
Travelan® record sales Global For personal use only + Full Year FY2024 AUD$4.9 million up 174% on (prior comparative period) pcp + June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on last quarter Australia + Full Year 2024 AUD$3.7 million up 223% on pcp + June 2024 Quarter AUD$1.0 million up
Slide 11: Status of product portfolio and key milestones
Status of product portfolio and key milestones Travelan® Clostridioides difficile Immuron’s Clinical Programs For personal use only MTEC 21-10-013 grant Phase 2 IMM-529 randomized clinical challenge study to Prevention of recurrent CDI infections Compound or examine a dosing regimen for Travelan® Va
Slide 12: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024 Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic which neutralizes C. difficile
Slide 13: IMM-124E Phase strategy
IMM-124E Phase 3 strategy Pre 2H 2024 1H 2025 2H 2025 Post For personal use only Phase 1 clinical study Additional topline data FDA meeting – Phase 3 Initiate Phase 3 Trial duration ~ 2 years (Baltimore, 1996) analysis August 2024 clinical protocol End of Phase 3 FDA meeting Phase 2 clinical study C
Slide 14: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 15: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172